These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 37558271)
21. Vaccination Strategies Against Mycobacterium tuberculosis: BCG and Beyond. Ferluga J; Yasmin H; Bhakta S; Kishore U Adv Exp Med Biol; 2021; 1313():217-240. PubMed ID: 34661897 [TBL] [Abstract][Full Text] [Related]
22. Epitope promiscuity and population coverage of Mycobacterium tuberculosis protein antigens in current subunit vaccines under development. Ong E; He Y; Yang Z Infect Genet Evol; 2020 Jun; 80():104186. PubMed ID: 31923726 [TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of routine adolescent vaccination with an M72/AS01 Harris RC; Quaife M; Weerasuriya C; Gomez GB; Sumner T; Bozzani F; White RG Nat Commun; 2022 Feb; 13(1):602. PubMed ID: 35105879 [TBL] [Abstract][Full Text] [Related]
24. Tuberculosis vaccines and prevention of infection. Hawn TR; Day TA; Scriba TJ; Hatherill M; Hanekom WA; Evans TG; Churchyard GJ; Kublin JG; Bekker LG; Self SG Microbiol Mol Biol Rev; 2014 Dec; 78(4):650-71. PubMed ID: 25428938 [TBL] [Abstract][Full Text] [Related]
25. Importance of differential identification of Mycobacterium tuberculosis strains for understanding differences in their prevalence, treatment efficacy, and vaccine development. Chae H; Shin SJ J Microbiol; 2018 May; 56(5):300-311. PubMed ID: 29721826 [TBL] [Abstract][Full Text] [Related]
26. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
27. Novel vaccination strategies and approaches against human tuberculosis. Méndez-Samperio P Scand J Immunol; 2019 Aug; 90(2):e12774. PubMed ID: 31054193 [TBL] [Abstract][Full Text] [Related]
28. [Recent progress in mycobacteriology]. Okada M; Kobayashi K Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602 [TBL] [Abstract][Full Text] [Related]
29. Natural and trained innate immunity against Mycobacterium tuberculosis. Ferluga J; Yasmin H; Al-Ahdal MN; Bhakta S; Kishore U Immunobiology; 2020 May; 225(3):151951. PubMed ID: 32423788 [TBL] [Abstract][Full Text] [Related]
30. Antibiotic Treatment Shapes the Antigenic Environment During Chronic TB Infection, Offering Novel Targets for Therapeutic Vaccination. Chuang YM; Dutta NK; Gordy JT; Campodónico VL; Pinn ML; Markham RB; Hung CF; Karakousis PC Front Immunol; 2020; 11():680. PubMed ID: 32411131 [TBL] [Abstract][Full Text] [Related]
31. Developing vaccines to prevent sustained infection with Mycobacterium tuberculosis: Conference proceedings: National Institute of Allergy and Infectious Diseases, Rockville, Maryland USA, November 7, 2014. Vaccine Prevention of Sustained Mycobacterium tuberculosis Infection Summary Group Vaccine; 2015 Jun; 33(26):3056-64. PubMed ID: 25869889 [TBL] [Abstract][Full Text] [Related]
32. Genome wide approaches discover novel Mycobacterium tuberculosis antigens as correlates of infection, disease, immunity and targets for vaccination. Coppola M; Ottenhoff TH Semin Immunol; 2018 Oct; 39():88-101. PubMed ID: 30327124 [TBL] [Abstract][Full Text] [Related]
33. Impact of proteomics on anti-Mycobacterium tuberculosis (MTB) vaccine development. Jagusztyn-Krynicka EK; Roszczenko P; Grabowska A Pol J Microbiol; 2009; 58(4):281-7. PubMed ID: 20380137 [TBL] [Abstract][Full Text] [Related]
36. The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study. Portnoy A; Clark RA; Quaife M; Weerasuriya CK; Mukandavire C; Bakker R; Deol AK; Malhotra S; Gebreselassie N; Zignol M; Sim SY; Hutubessy RCW; Baena IG; Nishikiori N; Jit M; White RG; Menzies NA PLoS Med; 2023 Jan; 20(1):e1004155. PubMed ID: 36693081 [TBL] [Abstract][Full Text] [Related]
37. Tuberculosis vaccine: A journey from BCG to present. Fatima S; Kumari A; Das G; Dwivedi VP Life Sci; 2020 Jul; 252():117594. PubMed ID: 32305522 [TBL] [Abstract][Full Text] [Related]
38. Potential benefit of extended dose schedules of human papillomavirus vaccination in the context of scarce resources and COVID-19 disruptions in low-income and middle-income countries: a mathematical modelling analysis. Bénard É; Drolet M; Laprise JF; Jit M; Prem K; Boily MC; Brisson M Lancet Glob Health; 2023 Jan; 11(1):e48-e58. PubMed ID: 36521952 [TBL] [Abstract][Full Text] [Related]